Stock SLS SELLAS LIFE SCIENCES GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.52 USD +7.80% Intraday chart for SELLAS Life Sciences Group, Inc. +8.57% +43.40%
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ
Mar. 28 SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Powell Awaited -2-
DJ
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : SELLAS Life Sciences Group, Inc. - Special Call
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
AQ
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML
CI
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
AQ
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Top Midday Decliners
MT
Sector Update: Health Care Stocks Softer Friday Afternoon
MT
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall
MT
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
AQ
SELLAS Life Sciences Group, Inc. announced a financing transaction
CI
SELLAS Life Sciences : Material Event - Form 8-K
PU
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
AQ
SELLAS Life Sciences Group, Inc. Announces Executive Changes
CI
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
AQ
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLS Stock
  4. News SELLAS Life Sciences Group, Inc.